BioNTech SE (XBUL:22UA)
лв 110 0 (0%) Market Cap: 26.37 Bil Enterprise Value: -6.97 Bil PE Ratio: 0 PB Ratio: 1.25 GF Score: 50/100

BioNTech SE at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 12:00PM GMT
Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Okay. I believe we are live right now. Good morning, everyone, and welcome to the 42nd Annual Goldman Sachs Global Healthcare Conference. My name is Chris Shibutani. I'm a member of the research team in the biotech group. Joined by my colleague, CJ Zopf, we're very pleased to kick off this year's conference with a presentation and discussion with BioNTech. Clearly one of the incredibly emerging stories from 2020, increasing relevant for global investors.

Joining us today, we have Ryan Richardson, Chief Strategic Officer and Managing Director. Ryan, thank you so much for joining us today.

Ryan Richardson
BioNTech SE - Chief Strategy Officer, MD & Member of Management Board

Thank you, Chris. Good to be with you.

Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Before we kick off, I am required, apparently, to read a series of disclosures. So we'll see if we can get through this.

The

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot